Lilly\'s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely...

More From BioPortfolio on "Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions"